PROSTATE CANCER IMMUNOTHERAPY BY TARGETING DENDRITIC CELLS IN VIVO USING RECEPTOR-SPECIFIC APTAMER CONJUGATED TO PROSTATE STEM CELL ANTIGEN (PSCA)-EN
$1,390,595FY2010Department of DefenseDOD
Duke University, Durham NC
Investigators
View source on USAspending →PROSTATE CANCER IMMUNOTHERAPY BY TARGETING DENDRITIC CELLS IN VIVO USING RECEPTOR-SPECIFIC APTAMER CONJUGATED TO PROSTATE STEM CELL ANTIGEN (PSCA)-EN · GrantIndex